SELLAS Life Sciences Group (SLS) Projected to Post Quarterly Earnings on Tuesday

SELLAS Life Sciences Group (NASDAQ:SLS) is anticipated to issue its Q1 2025 quarterly earnings data before the market opens on Tuesday, May 13th. Analysts expect the company to announce earnings of ($0.11) per share for the quarter.

SELLAS Life Sciences Group (NASDAQ:SLS) last announced its quarterly earnings results on Thursday, March 20th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.03. During the same quarter last year, the company posted ($1.34) EPS. On average, analysts expect SELLAS Life Sciences Group to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

SELLAS Life Sciences Group Trading Down 7.1%

Shares of NASDAQ SLS opened at $1.56 on Monday. SELLAS Life Sciences Group has a twelve month low of $0.77 and a twelve month high of $1.85. The company has a market capitalization of $147.49 million, a price-to-earnings ratio of -2.26 and a beta of 2.34. The firm has a 50-day moving average of $1.26 and a two-hundred day moving average of $1.19.

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc, a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company’s lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.